A Randomized, Controlled, Double-blind, Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial

Trial Profile

A Randomized, Controlled, Double-blind, Phase 3 Trial to Evaluate the Effects of Maternal or Neonatal Pneumococcal Conjugate Vaccination on Pneumococcal Carriage in Infants up to Nine Months of Age - The PROPEL Trial

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Tetanus toxoid (Primary)
  • Indications Pneumococcal infections
  • Focus Adverse reactions
  • Acronyms PROPEL
  • Most Recent Events

    • 02 Mar 2018 Planned End Date changed from 1 Feb 2019 to 1 Nov 2019.
    • 02 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Nov 2018.
    • 28 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top